Biogen Inc.
Biogen Inc. Announces New Chief Accounting Officer and Executive Transitions
Summary
On January 13, 2025, Biogen Inc. announced the appointment of Sean Godbout as Vice President, Chief Accounting Officer, and Global Corporate Controller, effective March 1, 2025. In this role, he will succeed Robin Kramer, who will transition to Chief Financial Officer upon the retirement of the current CFO, Michael McDonnell, also effective March 1, 2025. Sean Godbout has been with Biogen since 2007 and has held various roles of increasing responsibility, most recently as Global Corporate Controller.
Profitelligence Alerts
Get alerts for BIIB
Be first to know when Biogen Inc. files with the SEC.
Filing Categories
Advertisement
About Biogen Inc.
Biogen Inc. is a globally recognized biotechnology company committed to discovering, developing, and delivering innovative therapies for neurological diseases. With a focus on serious medical conditions, Biogen creates therapies aimed at treating conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company invests heavily in research and development to pioneer treatments that improve patients' quality of life and addresses critical unmet medical needs. Biogen's influence spans various therapeutic areas in the healthcare sector, making notable strides in both neurodegenerative and rare diseases. The company's portfolio includes a range of biologics, gene therapy, and small molecule drugs, highlighting its strategic diversity. As a prominent player within the biopharmaceutical industry, Biogen collaborates with academic institutions, research organizations, and other biotech firms to enhance its research pipeline and bring new solutions to market. Biogen's role in the financial markets is underscored by its contributions to healthcare innovation and its impact on global health outcomes. Headquartered in Cambridge, Massachusetts, Biogen continues to leverage its scientific expertise and industry alliances to remain at the forefront of biotechnology, influencing both investors and the broader medical community.
Official SEC Documents
Advertisement